Petrovski, Ognen
Preferred name
Petrovski, Ognen
Official Name
Petrovski, Ognen
Main Affiliation
Email
ognen.petrovski@medf.ukim.edu.mk
3 results
Now showing 1 - 3 of 3
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Clearance of vancomycin calculated according to different formulas and their influence against different pharmacokinetic parameters(Medical Faculty, Ss. Cyril and Methodius University in Skopje, 2015); ; ; Zdravkovska, Milka - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Antibiotic Consumption in Hospitalized Children at the University Clinic for Pediatric Diseases – Skopje(Scientific Foundation SPIROSKI, 2020-06-10); ; ; <jats:p>BACKGROUND: The misuse and overuse of antibiotics contribute to the development of antimicrobial residence. Official data in EU/ EEA in 2017 in the hospital sector suggested that the consumption is lowest in the Netherlands, with 1 DDD per 1,000 inhabitants/day in comparison with Finland, with 2.8 DDD/TID. AIM: The aim of this study was to analyze data on the scope and structure of the antibiotic prescription in pediatric patients at University Children’s Hospital for period of 3 months in 2018 and 2019. MATERIALS AND METHODS: The data for antibiotic consumption were obtained from a hospital pharmacy, which are ordinated to hospitalized patients. RESULTS: The total amount of utilized antibacterial drugs with ATC code J01 for first quarter in 2018 is 33.65 DDD/100BD in comparison to the first quarter of 2019 when it declined to 32.09 DDD/100BD. The most consummated antibiotics in the first trimester of both years were the group of cephalosporins, especially the 3rd- and 4th-generation parenteral cephalosporins with from 16.96 to 19.25 DDD/100BD in the evaluated period. Decrease of penicillin’s, carbapenems, macrolides and quinolones were confirmed in the analyzed period. The most commonly used drugs remain ceftriaxone – 13.49 DDD/100BD in 2018 and increased to 14.41 DDD/100BD in 2019, followed by amikacin 3.21 DDD/100BD in 2018 and increased to 3.50 DDD/100BD in 2019 but azithromycin consumption significantly declined from 1.97 DDD/100BD to 0.81 DDD/100BD administered orally. The third most commonly utilized antibiotic in first quarter of 2019 become meropenem, antimicrobial drug from the group of carbapenems with 2.71 DDD/100BD. CONCLUSION: The benefits of monitoring the antibiotic prescribed pattern are critical due to the fact that they provide adequate data on consumption of antibiotics and adherence to guidelines.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effects of Rosiglitazone on Metabolic Parameters and Adiponectin Levels in Fructose-Fed Rats(Scientific Foundation Spiroski (publications), 2009-03-01); ; ; ; Dimitrovski, ChedoAim. To investigate the effect of the peroxisome proliferators-activator receptor gamma agonist, rosiglitazone, on metabolic parameters and adiponectin levels in an animal model of the metabolic syndrome. Material and methods. Metabolic syndrome was induced in 32 male Wistar rats by adding a fructose in drinking water for 12 weeks. During the last 4 weeks, 16 rats were treated with rosiglitazone (5 mg/kg/day), while the remaining 16 did not receive any medication (fructose group). Another control group consumed standard rat chow and water for 12 weeks. Results. Chronic fructose administration induced a significant increase in systolic blood pressure (SBP), body weight, serum triglycerides (TG), free fatty acids (FFA), insulin, glucose AUC0-120 (during oral glucose tolerance test) and decreased serum high density lipoprotein (HDL) cholesterol and adiponectin concentrations compared with the control group. Treatment with rosiglitazone over the final 4 weeks reversed these effects and significantly reduced SBP, TG, FFA, insulin concentrations and glucose AUC0-120 compared with the fructose group. In addition, rosiglitazone increased serum levels of adiponectin twofold from 3.44 ± 0.46 to 7.03 ± 1.30 μg/ ml. Conclusion. This study indicates that rosiglitazone treatment improves the components of the metabolic syndrome, which is accompanied with an increase in adiponectin concentrations.